RxDoctor Payments DataLook up a doctor →

Frank Perrino, MD

Family Medicine · Cincinnati, OHNPI 1265477244

Payments from drug & device makers

$48,702in general payments, 2019–2025

Across 497 payments — averaging $97.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astrazeneca UK Limited$40K
  • AstraZeneca$1K
  • Lilly USA, LLC$892
  • Novo Nordisk$847
  • Pfizer$727
  • AbbVie$596
  • plus $5K from 40 others

What the payments were for

  • Food & beverage$8,800100%
  • Education$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,702 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$65,799
Medicare patients
194
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$152,722
JardianceEmpagliflozin112$125,684
TrulicityDulaglutide78$97,987
EliquisApixaban121$88,694
FarxigaDapagliflozin Propanediol68$71,956
XareltoRivaroxaban88$65,749
Bydureon BciseExenatide Microspheres13$30,264
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$29,562
RybelsusSemaglutide14$17,190
SymbicortBudesonide/Formoterol Fumarate41$15,165
EntrestoSacubitril/Valsartan11$14,157
LinzessLinaclotide16$13,689
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$13,269
MounjaroTirzepatide12$13,261
MyrbetriqMirabegron18$8,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$847$169,912116 claims
Boehringer IngelheimJardiance$357$125,684112 claims
Lilly USA, LLCTrulicity, Mounjaro$892$111,24890 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$1,034$100,390124 claims
PfizerEliquis$727$88,694121 claims
Johnson & JohnsonXarelto$572$65,74988 claims
GSKTrelegy Ellipta$226$29,56228 claims
NovartisEntresto$441$14,15711 claims
AbbVieLinzess$596$13,68916 claims
Astellas Pharma US IncMyrbetriq$112$8,31218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →